Acceleron Pharma is focused on developing therapeutics for metabolic and musculoskeletal diseases affecting millions of people. The company was founded with a robust intellectual property portfolio and a deep knowledge of the largely untapped TGF-beta superfamily. This has led to a rich and exciting pipeline of product candidates. The company is advancing a number of programs into preclinical development and expects to have up to three product candidates in the clinic in 2006. Flagship Managing Partner Ed Kania is on the Board.

www.acceleronpharma.com